PCI 27483

Drug Profile

PCI 27483

Alternative Names: CRA-027483; PCI-27483

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Corporation
  • Developer Pharmacyclics
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Factor VIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pancreatic cancer; Venous thromboembolism

Most Recent Events

  • 26 May 2015 Pharmacyclics has been acquired by AbbVie
  • 04 Jun 2013 Pharmacyclics completes Part A of a 3-part Phase-II trial in Pancreatic cancer in USA (NCT01020006)
  • 11 Oct 2012 Pharmacyclics and Novo Nordisk enter into a strategic license agreement for PCI 27483 in a restricted disease indication outside of oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top